| dc.contributor.author | Gaikwad, Anil Bhanudas | |
| dc.date.accessioned | 2023-12-19T09:14:05Z | |
| dc.date.available | 2023-12-19T09:14:05Z | |
| dc.date.issued | 2017-07 | |
| dc.identifier.uri | https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.13946 | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13450 | |
| dc.description.abstract | One of the protective actions of angiotensin converting enzyme-2 (ACE2) is the inactivation of angiotensin II. Expression and activity of ACE2 was reduced in glomeruli of diabetic patients and in animal models of diabetes. Recently the potential role of recombinant ACE2 administration in preventing diabetic nephropathy (DN) has been shown. Here we have tested the effects of the ACE2 activator, diminazene aceturate (DIZE), in a model of DN. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wiley | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Diminazene | en_US |
| dc.subject | Diabetic nephropathy | en_US |
| dc.title | Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||